Completed PHASE1 INTERVENTIONAL NCT00181545

Safety Study of Individualised Radiation Dose Determination for Lung Cancer Patients.

Individualised Radiation Dose Determination on Basis of Normal Tissue Dose Constraints in Patients With Non-Small-Cell Lung Cancer: A Phase I Study

Sponsor: Maastricht Radiation Oncology

Conditions Non-Small-Cell Lung Carcinoma

Interventions escalation of dose (radiotherapy treatment)

Updated 5 times since 2017 Last updated: Jun 29, 2009 Started: Dec 31, 2004 Primary completion: May 31, 2008 Completion: May 31, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Non-Small-Cell Lung Carcinoma and is currently completed. Maastricht Radiation Oncology leads this study, which shows 5 recorded versions since 2004 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Jan 2017 — Jun 2018 [monthly]

Completed PHASE1

First recorded

Dec 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Maastricht Radiation Oncology

Data source: Maastricht Radiation Oncology

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Heerlen, Netherlands